Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
暂无分享,去创建一个
M. J. van den Bent | A. Brandes | N. Butowski | A. Idbaih | A. Omuro | G. Tabatabai | Y. Muragaki | K. Tatsuoka | D. Reardon | M. Khasraw | A. Fu | P. Roth | J. Baehring | Xiaozhong Qian | O. Bähr | M. Lim | A. Carpentier | M. Weller | U. Lassen | G. Lombardi | J. Sepúlveda | E. Vauléon | Yanfang Liu | A. Sumrall | P. Mulholland | Alexandros G Chalamandaris | V. Potter | A. D. Di Giacomo | T. Cloughesy
[1] Jennie W. Taylor,et al. CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548 , 2021, Neuro-Oncology.
[2] A. Murphy,et al. Sequence of αPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses , 2021, Science Immunology.
[3] G. Reifenberger,et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood , 2020, Nature Reviews Clinical Oncology.
[4] M. Weller,et al. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma , 2020, JAMA oncology.
[5] Raymond Y Huang,et al. Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. , 2020, Neuro-oncology.
[6] M. Weller,et al. ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE , 2019, Neuro-Oncology.
[7] O. Elemento,et al. Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system , 2019, Genome Medicine.
[8] M. Gilbert,et al. MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials , 2018, Clinical Cancer Research.
[9] Jill S Barnholtz-Sloan,et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. , 2018, Neuro-oncology.
[10] M. Atkins,et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain , 2018, The New England journal of medicine.
[11] B. Nahed,et al. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors , 2018, Nature Network Boston.
[12] M. Weller. Where does O6‐methylguanine DNA methyltransferase promoter methylation assessment place temozolomide in the future standards of care for glioblastoma? , 2018, Cancer.
[13] M. Ahluwalia,et al. Efficacy of immune checkpoint inhibitors in patients with brain metastasis from NSCLC, RCC, and melanoma. , 2018 .
[14] F. Lieberman,et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial , 2017, JAMA.
[15] J. Huse,et al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy , 2017, Neuro-oncology.
[16] M. Weller,et al. The network of immunosuppressive pathways in glioblastoma , 2017, Biochemical pharmacology.
[17] G. Fuller,et al. PD-L1 expression and prognostic impact in glioblastoma. , 2016, Neuro-oncology.
[18] D. Hafler,et al. Prospects of immune checkpoint modulators in the treatment of glioblastoma , 2015, Nature Reviews Neurology.
[19] M. Weller,et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. , 2015, Neuro-oncology.
[20] S. Gautam,et al. Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma , 2015, British Journal of Cancer.
[21] E. Golden,et al. Radiotherapy and immunogenic cell death. , 2015, Seminars in radiation oncology.
[22] Walter J Curran,et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] John Wong,et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. , 2013, International journal of radiation oncology, biology, physics.
[24] P. Fayers,et al. Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. , 2012, European journal of cancer.
[25] Susan M. Chang,et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] G. Reifenberger,et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? , 2010, Nature Reviews Neurology.
[27] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[28] Robert C. Rose,et al. Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor1 , 2005, The Journal of Immunology.
[29] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[30] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[31] S. Gerson. MGMT: its role in cancer aetiology and cancer therapeutics , 2004, Nature Reviews Cancer.
[32] Luca Regli,et al. Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.
[33] Scar,et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.